Novo Nordisk A/S (NYSE:NVO) Shares Bought by U.S. Capital Wealth Advisors LLC

U.S. Capital Wealth Advisors LLC grew its holdings in shares of Novo Nordisk A/S (NYSE:NVO) by 0.6% during the fourth quarter, according to its most recent Form 13F filing with the SEC. The firm owned 15,421 shares of the company’s stock after purchasing an additional 90 shares during the period. U.S. Capital Wealth Advisors LLC’s holdings in Novo Nordisk A/S were worth $1,595,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds also recently modified their holdings of NVO. Pacific Center for Financial Services increased its holdings in shares of Novo Nordisk A/S by 100.0% in the 3rd quarter. Pacific Center for Financial Services now owns 270 shares of the company’s stock worth $25,000 after acquiring an additional 135 shares during the period. Bell Investment Advisors Inc increased its holdings in shares of Novo Nordisk A/S by 79.9% in the 3rd quarter. Bell Investment Advisors Inc now owns 286 shares of the company’s stock worth $26,000 after acquiring an additional 127 shares during the period. CNB Bank acquired a new stake in shares of Novo Nordisk A/S in the 4th quarter worth about $26,000. Tyler Stone Wealth Management increased its holdings in shares of Novo Nordisk A/S by 100.0% in the 3rd quarter. Tyler Stone Wealth Management now owns 292 shares of the company’s stock worth $27,000 after acquiring an additional 146 shares during the period. Finally, West Paces Advisors Inc. increased its stake in Novo Nordisk A/S by 100.0% during the 3rd quarter. West Paces Advisors Inc. now owns 300 shares of the company’s stock valued at $27,000 after buying an additional 150 shares during the period. 11.54% of the stock is owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

Several equities analysts have commented on the stock. UBS Group assumed coverage on shares of Novo Nordisk A/S in a research note on Tuesday, January 16th. They set a “neutral” rating on the stock. Cantor Fitzgerald reissued an “overweight” rating and set a $160.00 target price on shares of Novo Nordisk A/S in a research note on Thursday, April 18th. Morgan Stanley assumed coverage on shares of Novo Nordisk A/S in a research note on Tuesday, January 23rd. They set an “overweight” rating and a $120.00 target price on the stock. Finally, BMO Capital Markets assumed coverage on shares of Novo Nordisk A/S in a research note on Friday, April 12th. They set an “outperform” rating and a $163.00 target price on the stock. Two equities research analysts have rated the stock with a hold rating, six have given a buy rating and one has given a strong buy rating to the company’s stock. Based on data from MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus target price of $133.60.

Novo Nordisk A/S Stock Performance

Shares of NVO opened at $121.65 on Monday. Novo Nordisk A/S has a one year low of $75.56 and a one year high of $138.28. The company has a 50-day moving average of $127.20 and a two-hundred day moving average of $113.10. The stock has a market cap of $545.91 billion, a price-to-earnings ratio of 42.43, a PEG ratio of 1.93 and a beta of 0.43. The company has a debt-to-equity ratio of 0.17, a current ratio of 0.70 and a quick ratio of 0.50.

About Novo Nordisk A/S

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.